Google DeepMind does not sell products under its own name. It is a cost center inside Alphabet that builds the models Google monetizes: Gemini powers AI Overviews and AI Mode in Search (supporting ad revenue), the Gemini app and Google One AI subscriptions, Gemini for Workspace, and pay-per-token Gemini APIs on Google AI Studio and Vertex AI in Google Cloud. Its UK company, DeepMind Technologies Limited, books revenue mainly from research and development services provided to other Alphabet companies, reaching more than $1.98 billion (£1.5 billion) in 2023. Drug discovery is commercialized separately through Isomorphic Labs, an Alphabet company that Hassabis also leads.